A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Pemafibrate (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kowa
- 31 Aug 2018 Biomarkers information updated
- 09 Feb 2018 Status changed from not yet recruiting to recruiting.
- 24 Nov 2017 New trial record